Medpace (NASDAQ:MEDP) CEO August Troendle Sells 5,128 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,128 shares of Medpace stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $601.37, for a total transaction of $3,083,825.36. Following the sale, the chief executive officer directly owned 914,162 shares in the company, valued at $549,749,601.94. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Medpace Price Performance

MEDP traded down $1.23 on Friday, reaching $590.09. The company’s stock had a trading volume of 184,581 shares, compared to its average volume of 417,092. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00. The business’s 50 day moving average is $537.32 and its 200 day moving average is $420.81. The stock has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the company posted $3.01 EPS. Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MEDP shares. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. William Blair reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, July 23rd. Finally, Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $487.18.

Hedge Funds Weigh In On Medpace

Several hedge funds and other institutional investors have recently made changes to their positions in MEDP. Quent Capital LLC acquired a new stake in Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace during the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group grew its stake in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after purchasing an additional 71 shares in the last quarter. Finally, Whittier Trust Co. increased its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after purchasing an additional 35 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.